BCE Inc.: Barclays cuts target price to $24 from $25
BCE•Barclays cut its target price for BCE Inc. to $24 from $25.
Related News
iBio plans first-in-human trial of obesity drug candidate IBIO-610 in H1 2027
IBIO•
Merck names Cressey managing partner Paul Diaz to board effective Nov. 1, 2026
MRK•
JPMorgan expects FY2026 net interest income of about $106.2 billion
JPM•
Beam Therapeutics reports initial Phase 1/2 data for BEAM-301 in glycogen storage disease type Ia trial
BEAM•
Opus Genetics presents at Chardan Annual Healthcare Conference
IRD•